These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25485495)

  • 1. The metabolically-modulated stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy.
    Rovida E; Peppicelli S; Bono S; Bianchini F; Tusa I; Cheloni G; Marzi I; Cipolleschi MG; Calorini L; Sbarba PD
    Cell Cycle; 2014; 13(20):3169-75. PubMed ID: 25485495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
    Bono S; Dello Sbarba P; Lulli M
    Stem Cell Res; 2018 Apr; 28():33-38. PubMed ID: 29414416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One more stem cell niche: how the sensitivity of chronic myeloid leukemia cells to imatinib mesylate is modulated within a "hypoxic" environment.
    Rovida E; Marzi I; Cipolleschi MG; Dello Sbarba P
    Hypoxia (Auckl); 2014; 2():1-10. PubMed ID: 27774462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
    Agarwal P; Isringhausen S; Li H; Paterson AJ; He J; Gomariz Á; Nagasawa T; Nombela-Arrieta C; Bhatia R
    Cell Stem Cell; 2019 May; 24(5):769-784.e6. PubMed ID: 30905620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.
    Del Poggetto E; Tanturli M; Ben-Califa N; Gozzini A; Tusa I; Cheloni G; Marzi I; Cipolleschi MG; Kashman Y; Neumann D; Rovida E; Dello Sbarba P
    Cell Cycle; 2015; 14(19):3146-54. PubMed ID: 26291130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamine Availability Controls BCR/Abl Protein Expression and Functional Phenotype of Chronic Myeloid Leukemia Cells Endowed with Stem/Progenitor Cell Potential.
    Poteti M; Menegazzi G; Peppicelli S; Tusa I; Cheloni G; Silvano A; Mancini C; Biagioni A; Tubita A; Mazure NM; Lulli M; Rovida E; Dello Sbarba P
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TARGETING LEUKEMIA STEM CELL RESISTANCE IN CHRONIC MYELOGENOUS LEUKEMIA.
    Bhatia R
    Trans Am Clin Climatol Assoc; 2019; 130():246-254. PubMed ID: 31516189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
    Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
    J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
    Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
    J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Culture Repopulation Ability (CRA) Assay and Incubation in Low Oxygen to Test Antileukemic Drugs on Imatinib-Resistant CML Stem-Like Cells.
    Cheloni G; Tanturli M
    Methods Mol Biol; 2016; 1465():73-85. PubMed ID: 27581140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A; Ahsan N; Rao RSP; Roder K; Yu X; Morgan J; Tepper A; Hines S; Zhang P; Treaba DO; Zhao TC; Olszewski AJ; Reagan JL; Liang O; Gruppuso PA; Dubielecka PM
    Mol Oncol; 2018 May; 12(5):630-647. PubMed ID: 29485707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells.
    Grandjenette C; Schnekenburger M; Gaigneaux A; Gérard D; Christov C; Mazumder A; Dicato M; Diederich M
    Cancer Lett; 2020 Jan; 469():468-480. PubMed ID: 31734352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
    Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
    FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.